For the fiscal year ending March 2026, TAKARA BIO INC. reported lower sales than in the previous fiscal year and an operating loss. The company attributed this to a global reduction in research budgets and intensifying competition in the Chinese market, and aims to restore profitability by pursuing structural reforms.
In its financial results report for the fiscal year ending March 2026, TAKARA BIO INC. announced a substantial decline in sales and earnings, with revenue of ¥40.318 billion, down 10.5% year on year, and an operating loss of ¥4.688 billion. The company explained that sales declined across all business segments, affected by a global reduction in research budgets and intensifying competition in the Chinese market.
The company outlined plans to pursue structural reforms to improve profitability, including reforms to group collaboration, such as the acquisition of Curio to strengthen its spatial analysis business, progress on investments in manufacturing facilities, and the continued development of gene therapy. The financial results report identifies these initiatives as factors supporting a future recovery in performance, while also pointing to the risks posed by reduced research budgets and intensifying competition.
The date of the next earnings announcement has not been determined. Trends in the company’s financial position, including an increase in interest-bearing debt and changes in its equity ratio, have been identified as areas of focus. The article is based on a summary by Buffett Code, and future performance is expected to vary depending on new contract wins and market conditions.